Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro
1994

Cisplatin and Taxol Work Together Against Ovarian Cancer Cells

Sample size: 3 publication Evidence: high

Author Information

Author(s): A.P. Jekunen, R.D. Christen, D.R. Shalinsky, S.B. Howell

Primary Institution: Helsinki University Central Hospital

Hypothesis

Does the combination of cisplatin and taxol have a schedule-dependent synergistic effect on human ovarian carcinoma cells?

Conclusion

The study found that taxol and cisplatin interact synergistically in a schedule-dependent manner to kill ovarian cancer cells.

Supporting Evidence

  • The combination of taxol and cisplatin showed CI values of 0.11, 0.25, and 0.39 at 20%, 50%, and 80% cell kill, indicating strong synergy.
  • Taxol exposure for 19 hours followed by 1 hour of concurrent exposure to cisplatin resulted in significant cell death.
  • DDP-resistant cells were found to be hypersensitive to taxol, suggesting a unique interaction.

Takeaway

When two cancer drugs, cisplatin and taxol, are used together, they can work better if given in a specific order. This means doctors need to think carefully about how they give these medicines.

Methodology

The study used human ovarian carcinoma cell lines and assessed the interaction between cisplatin and taxol using median effect analysis.

Statistical Information

P-Value

0.00098

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication